CompletedPhase 2NCT01627613

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Studying Acute lung injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Apeptico Forschung und Entwicklung GmbH
Principal Investigator
Roman Ullrich, Prof.
Medical University of Vienna
Intervention
AP301(drug)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
20122014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01627613 on ClinicalTrials.gov

Other trials for Acute lung injury

Additional recruiting or active studies for the same condition.

See all trials for Acute lung injury

← Back to all trials